Prospective Evaluation of the Utility of the Serum Free Light Chain Assay (FLC), Clonal Ig Vl Gene Identification and Troponin I Levels in a Phase II Trial of Risk-Adapted Intravenous Melphalan with Adjuvant Thalidomide and Dexamethasone for Newly Diagnosed Untreated Patients with Systemic Al Amyloidosis

Autor:	Rl Comenzo, P. Zhou, L. Reich, S. Costello, A. Quinn, S. Fircanis, L. Drake, C. Hedvat, J. Teruya-Feldstein, Da Filippa, M. Fleisher
Rok vydání:	2004
Předmět:	Melphalan medicine.medical_specialty business.industry medicine.medical_treatment Immunoglobulin light chain medicine.disease Gastroenterology Thalidomide Internal medicine Immunology Troponin I medicine AL amyloidosis business Adjuvant Gene Dexamethasone medicine.drug
Zdroj:	Amyloid and Amyloidosis ISBN: 9780429125249
DOI:	10.1201/9781420037494.ch57
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e0f95d8f2043dbc51bc290b4c32fd2d https://doi.org/10.1201/9781420037494.ch57 Zobrazit plný text záznamu